Northwire Canada EditionThursday, October 15, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
Other

Revive Therapeutics primes the pump on Bucillamine

By The Northwire Desk — AI Analysis Dec 15, 2025 · 17:09 RVV · 0.015 Revive Therapeutics Ltd
RVV · Price

Executive Summary

  • Revive Therapeutics Ltd. provided an update on its collaborative research study with Defence R&D Canada (DRDC) evaluating Bucillamine as a potential treatment for nerve agent-induced brain injury.
  • The study is expected to conclude with results in January 2026.
  • Any findings from the study will be released only with the express authorization of DRDC.

Key Details

  • Study Subject: Evaluation of Bucillamine as a potential treatment for nerve agent exposure.
  • Collaborator: Defence R&D Canada -- Suffield Research Centre (DRDC), an agency within the Canadian Department of National Defence.
  • Study Status: The research is ongoing and expected to conclude in January 2026.
  • Data Release Protocol: Findings will be released only with the express authorization of DRDC.
  • Company Focus: Revive Therapeutics is a life sciences company focused on R&D for infectious diseases and medical countermeasures, leveraging U.S. government regulatory incentives.

Notable Quotes

  • "After recent discussions with the DRDC, the research study on Bucillamine is expected to conclude with results in January, 2026."
  • "Any findings from the study will be released only with the express authorization of DRDC."
Read the original news release →

More from Revive Therapeutics Ltd

Jun 26, 2026 · 16:15

Cash-burning micro-cap biotech raises survival capital via dilutive private placement while pursuing repurposed drug for nerve agents and infectious diseases.

Financings May 20, 2026 · 07:45

Revive Therapeutics Patents Fuel Defense Strategy Amidst Price Consolidation

M&A / Property Mar 11, 2026 · 17:34

Revive Therapeutics advances bucillamine patents

M&A / Property Mar 11, 2026 · 07:30

Revive Therapeutics Strengthens Bucillamine IP Portfolio with North American Patent Filings for Nerve Agent Exposure and Granted Canadian Patent for Infectious Diseases

M&A / Property Dec 15, 2025 · 07:30

Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study

Other Nov 21, 2025 · 16:56

Revive talks DRDC study on bucillamine for nerve agents

Other